{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:57:47Z","timestamp":1786993067578,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jns.2024.123172","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:29:19Z","timestamp":1722972559000},"page":"123172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the \u2018suboptimal therapy\u2019 patient population"],"prefix":"10.1016","volume":"464","author":[{"given":"Mary","family":"Chappell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarunya","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tempest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"McCool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.jns.2024.123172_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","article-title":"Pathology and disease mechanisms in different stages of multiple sclerosis","volume":"333","author":"Lassmann","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2024.123172_bb0010","doi-asserted-by":"crossref","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","article-title":"Multiple sclerosis: geoepidemiology, genetics and the environment","volume":"9","author":"Milo","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2024.123172_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2024.123172_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.expneurol.2010.06.003","article-title":"New treatment strategies in multiple sclerosis","volume":"225","author":"Jones","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2024.123172_bb0030","series-title":"Tysabri","author":"European Medicines Agency","year":"2022"},{"issue":"9","key":"10.1016\/j.jns.2024.123172_bb0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2024.123172_bb0040","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123172_bb0045","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jns.2024.123172_bb0050","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.jns.2024.123172_bb0055","series-title":"Review Manager Web (RevMan Web). Version 5.4","year":"2023"},{"issue":"1","key":"10.1016\/j.jns.2024.123172_bb0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40169-018-0216-3","article-title":"The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study","volume":"7","author":"Mazdeh","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"8","key":"10.1016\/j.jns.2024.123172_bb0065","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1185\/03007995.2014.915802","article-title":"Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis","volume":"30","author":"Bergvall","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.jns.2024.123172_bb0070","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1007\/s10072-021-05127-z","article-title":"Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years","volume":"42","author":"Guerra","year":"2021","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2024.123172_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/jcm10091830","article-title":"Modified Rio score with platform therapy predicts treatment success with fingolimod and natalizumab in relapsing-remitting multiple sclerosis patients","volume":"10","author":"Jamroz-Wisniewska","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.123172_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.24339","article-title":"Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis","volume":"77","author":"Kalincik","year":"2015","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.123172_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223863","article-title":"The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a polish real-world population","volume":"14","author":"Kapica-Topczewska","year":"2019","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.jns.2024.123172_bb0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10072-012-1088-8","article-title":"Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice","volume":"34","author":"Lanzillo","year":"2013","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2024.123172_bb0095","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis","volume":"24","author":"Lorscheider","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jns.2024.123172_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000505778","article-title":"Effectiveness of fingolimod versus natalizumab as second-line therapy for relapsing-remitting multiple sclerosis in Spain: second-line GATE study","volume":"83","author":"Meca-Lallana","year":"2020","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123172_bb0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458511417481","article-title":"Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis","volume":"18","author":"Prosperini","year":"2012","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jns.2024.123172_bb0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","article-title":"Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis","volume":"264","author":"Prosperini","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2024.123172_bb0115","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.12659\/MSM.898270","article-title":"Safety and efficacy of fingolimod and natalizumab in multiple sclerosis after the failure of first-line therapy: single center experience based on the treatment of forty-four patients","volume":"22","author":"Puz","year":"2016","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"10.1016\/j.jns.2024.123172_bb0120","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: an observational study","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.jns.2024.123172_bb0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40273-021-01106-6","article-title":"Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom","volume":"40","author":"Spelman","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jns.2024.123172_bb0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/acn3.180","article-title":"Comparative efficacy of switching to natalizumab in active multiple sclerosis","volume":"2","author":"Spelman","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123172_bb0135","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3174\/ajnr.A4690","article-title":"White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis. AJNR: am","volume":"37","author":"Wiebenga","year":"2016","journal-title":"J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.jns.2024.123172_bb0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123172_bb0145","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri observational program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2024.123172_bb0150","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2024.123172_bb0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1352458520926869","article-title":"Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri observational program","volume":"27","author":"Wiendl","year":"2021","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jns.2024.123172_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13760-014-0308-9","article-title":"Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program","volume":"114","author":"van Pesch","year":"2014","journal-title":"Acta Neurol. Belg."},{"issue":"12","key":"10.1016\/j.jns.2024.123172_bb0165","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp-2017-316236","article-title":"Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events","volume":"88","author":"Calabrese","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2024.123172_bb0170","first-page":"75","article-title":"Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis","volume":"35","author":"Fernandez-Megia","year":"2011","journal-title":"Farm. Hosp."},{"issue":"3","key":"10.1016\/j.jns.2024.123172_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S0004-282X2013000300002","article-title":"Natalizumab adverse events are rare in patients with multiple sclerosis","volume":"71","author":"Fragoso","year":"2013","journal-title":"Arq. Neuropsiquiatr."},{"issue":"11","key":"10.1016\/j.jns.2024.123172_bb0180","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ejrad.2012.01.028","article-title":"The relationship between inflammatory activity and brain atrophy in natalizumab treated patients","volume":"81","author":"Magraner","year":"2012","journal-title":"Eur. J. Radiol."},{"issue":"9","key":"10.1016\/j.jns.2024.123172_bb0185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1590\/0004-282X20150098","article-title":"Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers","volume":"73","author":"Oliveira","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"issue":"3","key":"10.1016\/j.jns.2024.123172_bb0190","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2024.123172_bb0195","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s11055-014-9943-0","article-title":"Preliminary results of the \u201cSovet\u201d observational program for use of natalizumab in the treatment of patients with remitting multiple sclerosis","volume":"44","author":"Popova","year":"2014","journal-title":"Neurosci. Behav. Physiol."},{"issue":"3","key":"10.1016\/j.jns.2024.123172_bb0200","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1468-1331.2008.02519.x","article-title":"Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis","volume":"16","author":"Putzki","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2024.123172_bb0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10072-010-0346-x","article-title":"Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report","volume":"31","author":"Rinaldi","year":"2011","journal-title":"Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2024.123172_bb0210","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/13524585231151951","article-title":"Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis","volume":"29","author":"Daruwalla","year":"2023","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2024.123172_bb0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123172_bb0220","series-title":"ClinicalTrials.gov [Internet], Bethesda","article-title":"Safety and efficacy of natalizumab in combination with avonex in the treatment of multiple sclerosis. Identifier: NCT00030966","author":"Biogen.","year":"2002"},{"key":"10.1016\/j.jns.2024.123172_bb0225","series-title":"ClinicalTrials.gov [Internet], Bethesda","article-title":"Impact of natalizumab versus fingolimod in relapsing-remitting multiple sclerosis (RRMS) participants (REVEAL). Identifier: NCT02342704","author":"Biogen.","year":"2017"},{"issue":"10","key":"10.1016\/j.jns.2024.123172_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038861","article-title":"Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study","volume":"10","author":"Butzkueven","year":"2020","journal-title":"BMJ Open"},{"issue":"20","key":"10.1016\/j.jns.2024.123172_bb0235","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"Pt 7","key":"10.1016\/j.jns.2024.123172_bb0240","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jns.2024.123172_bb0245","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.msard.2015.07.007","article-title":"Optimizing therapy early in multiple sclerosis: an evidence-based view","volume":"4","author":"Ziemssen","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.jns.2024.123172_bb0250","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24003071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24003071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T17:21:12Z","timestamp":1724520072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24003071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":49,"alternative-id":["S0022510X24003071"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123172","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the \u2018suboptimal therapy\u2019 patient population","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123172"}}